886 Shares in United Therapeutics Corporation $UTHR Purchased by BAM Wealth Management LLC

BAM Wealth Management LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 886 shares of the biotechnology company’s stock, valued at approximately $432,000.

Other large investors have also added to or reduced their stakes in the company. AE Wealth Management LLC boosted its stake in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after acquiring an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC increased its stake in shares of United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares during the last quarter. Optimize Financial Inc purchased a new stake in shares of United Therapeutics during the 3rd quarter worth approximately $444,000. Simplify Asset Management Inc. bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $8,351,000. Finally, Osaic Holdings Inc. raised its holdings in shares of United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after purchasing an additional 33,662 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, January 12th. The stock was sold at an average price of $479.51, for a total value of $10,788,975.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $489.91, for a total value of $4,654,145.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at approximately $63,688.30. The trade was a 98.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 339,270 shares of company stock valued at $171,740,110 over the last three months. Company insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on UTHR. UBS Group upped their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Bank of America boosted their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Finally, Wells Fargo & Company lifted their price objective on United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 31st. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $586.00.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $564.81 on Monday. The firm’s 50 day moving average is $506.70 and its 200 day moving average is $479.77. The stock has a market capitalization of $24.76 billion, a P/E ratio of 20.24, a PEG ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $607.89.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the business earned $6.19 EPS. United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Positive Phase‑3 Tyvaso (IPF) data — the trial met its primary endpoint, supporting potential near‑term revenue upside from an expanded label and underpinning recent optimism. United Therapeutics reports positive results for lung drug
• Positive Sentiment: HC Wainwright raised price target and lifted multi‑year EPS forecasts (now Buy, $660 PT) and other brokers have moved targets higher — analyst upgrades increase buy-side conviction and support a higher valuation range. United Therapeutics Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Strong earnings‑surprise history and bullish earnings outlook — coverage notes (e.g., Zacks) highlight United Therapeutics’ track record of beating estimates, increasing the probability of another upside surprise at the next report. Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Elevated options activity — traders are positioning around the clinical news and upcoming earnings, which can amplify intraday volatility but is not a direct fundamental change. United Therapeutics Target of Unusually High Options Trading
• Neutral Sentiment: Coverage/valuation pieces and peer comparisons are proliferating — these shape expectations for how Tyvaso lifts long‑term value but won’t themselves change fundamentals. (See Zacks comparison with Catalyst (CPRX) and valuation write‑ups.) CPRX or UTHR: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Insider selling by senior executives (CEO, EVP, CFO) — multi‑million dollar disposals under 10b5‑1 plans may be read as profit‑taking and can add short‑term selling pressure despite being pre‑arranged. Rothblatt SEC Filing (Example)

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.